Trial Profile
A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-Muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; BCG
- Indications Bladder cancer; Urethral cancer
- Focus Therapeutic Use
- 19 Sep 2019 Status changed from active, no longer recruiting to completed.
- 10 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Aug 2019.
- 10 Jan 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2019.